Application of haematococcus pluvialis in preparation of medicine for preventing and treating chemotherapy-induced oral ulcer

By using erythrocytosaccharides to increase the barrier protein expression of oral ulcers and reduce the level of inflammatory factors, the problem of poor treatment effect of chemotherapy-induced oral ulcers in the prior art has been solved, and effective prevention and treatment effect is achieved, which is safe and economical.

CN118903222APending Publication Date: 2024-11-08HAINAN UNIV
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202410933961.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-12
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The prior art has poor efficacy and side effects in the treatment of chemotherapy-induced oral ulcers, and lacks effective prevention and treatment measures.

Method used

The pharmaceutical composition using Radix C. Radix C. as the main component, by increasing the expression of barrier proteins Occludin and ZO-1 in the oral mucosa, the content of inflammatory factors IL-6 and TNF-α is inhibited, and the inflammatory pathway of cGAS-STING is inhibited. Reduce oral inflammatory responses, thereby preventing and treating chemotherapy-induced and LPS-induced oral ulcers.

Benefits of technology

It significantly improves oral ulcers induced by chemotherapy drugs and LPS, improves barrier protein expression, reduces the level of inflammatory factors, is better than astaxanthin at the same dose, and is safe and cost-effective.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903222A_ABST
    Figure CN118903222A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of biological medicines, and particularly relates to application of haematococcus pluvialis in preparation of a medicine for preventing and treating chemotherapy-induced oral ulcer. Experiments show that the haematococcus pluvialis has a protective effect on chemotherapeutic drugs and LPS (lipopolysaccharide)-induced oral ulcers, and specifically, the expression quantity of barrier proteins Occludin and ZO-1 is increased; the content of inflammatory factors IL-6 and TNF-alpha is reduced; moreover, under the same dosage, the effect of the haematococcus pluvialis provided by the invention is superior to that of astaxanthin. Haematococcus pluvialis is high in safety, wide in source, low in cost and very suitable for being applied to prevention and treatment of oral ulcer. The invention not only provides a new drug source for the treatment of oral ulcer, but also opens up a new field for the application of haematococcus pluvialis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine technology, and more specifically, relates to the application of Haematococcus pluvialis in the preparation of a drug for preventing and treating chemotherapy-induced oral ulcers. Background Art

[0002] Oral ulcer is a common oral mucosal disease, an ulcerative reaction characterized by the appearance of rice-sized superficial ulcers in the mucosa of the gums, tongue, cheeks, palate, etc., with a prevalence rate of up to about 20%. Clinically, it often manifests as abnormal pain in the oral cavity, especially after stimulation such as talking and eating, which greatly affects the patient's language communication, normal eating and sleep, causing a significant decline in the quality of life, and even hindering its further treatment. Current studies believe that the pathological mechanism of oral ulcers mainly includes the following aspects: direct damage, inflammatory factor damage, and dysbacteriosis. Direct damage is chemotherapeutic drugs or other cytotoxic compounds, which have a direct damaging effect on normal oral mucosal cells. Chemotherapy (chemotherapy) is one of the main methods for treating malignant tumors. Oral ulcers are one of the common toxic and side effects that occur in patients with malignant tumors during chemotherapy. The normal oral microbial flora of the human body is dominated by Gram-positive bacteria. However, when the oral flora is unbalanced, such as in cancer patients, the oral microbial flora is easily affected by the disease. When receiving radiotherapy, chemotherapy and other treatments, the oral microbial flora changes from being dominated by Gram-positive bacteria to being dominated by Gram-negative bacteria. The cell wall of Gram-negative bacteria is mainly composed of lipopolysaccharide (LPS), which is a key substance activated by inflammation, which will aggravate the inflammatory response of the oral mucosa and cause oral ulcers.

[0003] Currently, the treatments for such complications are mostly gargles, saline, tin powder, glucocorticoids, antibacterial preparations, etc., but the efficacy is poor and some have side effects. Therefore, it is extremely urgent to find new therapeutic drugs to improve the quality of life of patients.

[0004] Hoematococcus pluvialis (HP) is a marine algae belonging to the genus Haematococcus, Chlorophyta. It is known as an economic microalgae with high nutritional value because it is rich in bioactive substances such as amino acids, trans-3-indoleacrylic acid, ω-3 unsaturated fatty acids and astaxanthin. Studies have shown that Haematococcus pluvialis extract can promote cell regeneration, reduce the accumulation of senescent cells, and maintain the body's balance (Yin Z, Wang M, Zeng M. Novel Pickering emulsion stabilized by natural fiber polysaccharide-protein extracted from Haematococcus pluvialis residues [J]. Food Hydrocolloids, 2023, 134: 108048.), and effectively prolong the actual lifespan of yeast by reducing the level of intracellular reactive oxygen, promoting the level of mitochondrial membrane potential and accumulating glycogen (Wang M, Xu P, Liao L, et al. Haematococcus Pluvialis Extends Yeast Lifespan and Improves Slc25a46 Gene Knockout-Associated Mice Phenotypic Defects [J]. MOLECULAR NUTRITION & FOOD RESEARCH, 2021, 65 (24).). Due to its excellent antioxidant and anti-aging properties, Haematococcus pluvialis has been widely used in health care products, feed, cosmetics and other fields. However, there are many other active effects of Haematococcus pluvialis that have yet to be explored. Summary of the invention

[0005] The technical problem to be solved by the present invention is to overcome the defects and shortcomings of the limited clinical drug treatment effect of the prior art, and to provide the use of Haematococcus pluvialis in the preparation of drugs for preventing and treating oral ulcers.

[0006] Another object of the present invention is to provide an application of a pharmaceutical composition in the preparation of a drug for preventing and treating oral ulcers, wherein the pharmaceutical composition comprises Haematococcus pluvialis.

[0007] The above-mentioned purpose of the present invention is achieved through the following technical solutions:

[0008] Application of Haematococcus pluvialis in the preparation of medicines for preventing and treating oral ulcers.

[0009] The main chemical components of the Haematococcus pluvialis of the present invention are amino acids, and the top ten substances in its chemical components are L-leucine with a relative content of 47.622%, astaxanthin with a relative content of 11.204%, trans-3-indole acrylic acid with a relative content of 9.617%, L-proline with a relative content of 6.309%, citric acid with a relative content of 5.919%, α-linolenic acid with a relative content of 3.826%, L-glutamic acid with a relative content of 3.735%, p-hydroxycinnamic acid with a relative content of 3.573%, L-tyrosine with a relative content of 1.703%, and L-threonine with a relative content of 1.298%. In addition to astaxanthin, Haematococcus pluvialis also contains a large number of other active ingredients such as amino acid components, organic acids and small molecule active peptides, which work together with astaxanthin to exert a synergistic effect and can better improve oral ulcers. Specifically in the embodiment of the present application, under the same dose, the improvement effect of Haematococcus pluvialis on rats with oral ulcers is significantly better than astaxanthin.

[0010] Furthermore, the oral ulcer is a chemotherapy-induced oral ulcer or a lipopolysaccharide (LPS)-induced oral ulcer.

[0011] Furthermore, the chemotherapy-induced oral ulcer is induced by chemotherapy drugs.

[0012] Furthermore, the chemotherapy drug is one or more of 5-fluorouracil, methotrexate, cyclophosphamide, and irinotecan.

[0013] Furthermore, the method for preventing and treating oral ulcers is to increase the expression levels of Occludin and ZO-1 proteins.

[0014] Furthermore, the method for preventing and treating oral ulcers is to reduce the content of the inflammatory factor IL-6.

[0015] Specifically, the present invention has experimentally demonstrated that Haematococcus pluvialis can significantly increase the expression of barrier proteins Occludin and ZO-1 in the oral mucosa in oral ulcers induced by the chemotherapy drug 5-fluorouracil, and reduce the content of inflammatory factor IL-6, and the effect is better than that of astaxanthin at the same dose.

[0016] At the same time, the present invention proves through experiments that the Haematococcus pluvialis can increase the expression of Occludin and ZO-1 proteins after LPS induction treatment, and reduce the content of inflammatory factors IL-6 and TNF-α. And the effect is better than astaxanthin at the same dose.

[0017] Furthermore, the Haematococcus pluvialis inhibits the cGAS-STING inflammatory pathway, reduces the level of oral inflammatory factors, improves oral inflammatory response, and thus reduces the occurrence of oral ulcers.

[0018] Furthermore, the medicine also includes pharmaceutically acceptable excipients.

[0019] Furthermore, the dosage form of the drug is an oral patch, an oral lozenge, a mouthwash, a spray, a smear, an oral agent or an injection.

[0020] Additionally, the present invention protects the use of a pharmaceutical composition in the preparation of a drug for preventing and treating oral ulcers, wherein the pharmaceutical composition comprises Haematococcus pluvialis.

[0021] Furthermore, the pharmaceutical composition also includes pharmaceutically acceptable excipients.

[0022] The present invention has the following beneficial effects:

[0023] The present invention provides the use of Haematococcus pluvialis in the preparation of a drug for preventing and treating oral ulcers induced by chemotherapy and LPS. The present invention proves through animal and cell experiments that Haematococcus pluvialis has a protective effect on oral ulcers induced by chemotherapy drugs and LPS, specifically by increasing the expression of barrier proteins Occludin and ZO-1; reducing the content of inflammatory factors IL-6 and TNF-α; and at the same dose, the effect of the Haematococcus pluvialis of the present invention is better than astaxanthin. Haematococcus pluvialis has high safety, wide sources, low cost, and is very suitable for use in the prevention and treatment of oral ulcers. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] Figure 1 This is a diagram of the pathological condition of the oral mucosa of rats in Example 2 of the present invention. Figure 1 (A) is a picture of the oral mucosa of a rat (the red arrow indicates the ulcer part); Figure 1 (B) is a micrograph of sections stained with HE, SR and Masson, and a statistical graph of the quantitative analysis data of Masson-stained collagen fiber accumulation.

[0025] Figure 2 The expression level of barrier proteins Occludin and ZO-1 in rat oral mucosal tissue and human normal oral epithelial keratinocytes. Figure 2 (A) is a representative graph and statistical graph of ZO-1 protein expression levels obtained from Western Blot experiments; Figure 2 (B) is a representative graph and statistical graph of Occludin protein expression level obtained from Western Blot experiment; Figure 2 (C) is a fluorescence imaging micrograph and data statistics of the distribution of Occludin protein determined by cell immunofluorescence method; Figure 2 (D) is a fluorescence imaging micrograph and data statistics of the distribution of ZO-1 protein determined by cell immunofluorescence method.

[0026] Figure 3It is a statistical chart of the levels of inflammatory factors IL-6 in rat oral mucosal tissue and IL-6 and TNF-α in normal human oral epithelial keratinocytes; Figure 3 (A) is a statistical graph of TNF-α content in human oral epithelial keratinocytes; Figure 3 (B) is a statistical graph of IL-6 content in human oral epithelial keratinocytes; Figure 3 (C) is a statistical chart of IL-6 content in rat oral mucosal tissue.

[0027] Figure 4 This is the expression diagram of proteins related to the cGAS-STING signaling pathway in human oral epithelial keratinocytes. Figure 4 (A) is a representative graph and statistical graph of STING protein expression levels obtained from Western Blot experiments; Figure 4 (B) is a representative graph and statistical graph of cGAS protein expression levels obtained from Western Blot experiments; Figure 4 (C) is a representative graph and data statistical graph of P-TBK1 protein expression level obtained from Western Blot experiment.

[0028] Note: Figure 1 to Figure 4 **P<0.01, ***P<0.001 compared with the Control group, #P<0.05, ##P<0.01, ###P<0.001 compared with the 5-FU group or LPS group. DETAILED DESCRIPTION

[0029] The present invention is further described below in conjunction with the accompanying drawings and specific examples, but the examples do not limit the present invention in any form. Unless otherwise specified, the reagents, methods and equipment used in the present invention are conventional reagents, methods and equipment in the art.

[0030] Unless otherwise specified, the reagents and materials used in the following examples are commercially available.

[0031] Example 1 Chemical composition analysis of Haematococcus pluvialis

[0032] Thermo QE plus liquid chromatography tandem high-resolution mass spectrometry and Compound discover data processing software were used to analyze the chemical components of Haematococcus pluvialis. Haematococcus pluvialis (Yunnan Alcon Biotechnology Co., Ltd.)

[0033] Experimental methods:

[0034] Sample pretreatment: 200 mg of Haematococcus pluvialis was added with 10 mL of 50% methanol aqueous solution (v:v, methanol: water = 50:50), ultrasonicated for 30 min, 1 mL of supernatant was placed in a centrifuge tube and centrifuged at 14000 rpm for 5 min, the supernatant was filtered through a 0.22 μm microporous membrane, and then placed in a sample injection bottle for UHPLC-MS / MS analysis. The blank sample was treated under the same conditions.

[0035] Liquid phase conditions: chromatographic column: ACQUITY UPLC HSST3 column (2.1x100mm, 1.8μm), column temperature: 35°C, injection volume: 10μL, flow rate: 0.3mL / min. Mobile phase: A (deionized water, containing 0.1% formic acid); B (acetonitrile, containing 0.1% formic acid), gradient elution.

[0036] Mass spectrometry conditions: QExactive Orbitrap high-resolution mass spectrometer was used for mass spectrometry data acquisition. The detection mode was FullMS-ddMS2. Positive and negative ion modes were scanned separately, with a scan range of m / z 100-1200. The MS1 resolution was set to 70000, the MS2 resolution was set to 17500, the ion source voltage was 3.2 kV, the capillary ion transfer tube temperature (Capillary temp) was 320°C, the auxiliary gas heating temperature (Aux gas heater temp) was 350°C, the sheath gas flow rate was 40 L / min, the auxiliary gas flow rate (Aux gas flowrate) was 15 L / min, the AGCTarget was set to 1e6 (1e6 means 1 times 10 to the sixth power), the TopN was set to 5, and the collision energy for triggering the MS2 scan used a stepped fragmentation voltage NCE, which was set to 30, 40, and 50.

[0037] Experimental results:

[0038] Compound discover 3.2 software was used to extract the characteristic peaks of the original Raw mass spectrometry data. The mass deviations of characteristic peak element matching, molecular formula prediction and isotope distribution matching were set to within 5ppm. The mzCloud online database and the locally built mzVault Chinese medicine natural product database were used for characteristic peak identification. The positive result screening criteria were mass deviation <5ppm, consistent with isotope distribution and mzVault best match database matching score>70 points. The specific results are shown in Table 1. It can be seen from Table 1 that the main chemical components in Haematococcus pluvialis are amino acids, among which L-leucine has the highest content, with a relative content of 47.622%.

[0039] Table 1 The top ten substances in the chemical composition of Haematococcus pluvialis

[0040]

[0041] Example 2 Haematococcus pluvialis can improve oral ulcers and pathological conditions in rats

[0042] Experimental materials: SD rats (Beijing Sibeifu Biotechnology Co., Ltd.; Animal Certificate No.: NO.110324231106182758); Haematococcus pluvialis (Yunnan Alcon Biotechnology Co., Ltd.); 5-fluorouracil (Shanghai Aladdin Biochemical Technology Co., Ltd.; CAS: 51-21-8).

[0043] Experimental methods: 42 SPF male SD rats weighing 170±10g were raised in a standard SPF environment and fed with standard feed. The rats had free access to water. After one week of adaptive feeding with normal feed, the animals were randomly divided into 5 groups, with 12 rats in each group. First, 14 days before modeling, the 5-FU+HP group and the 5-FU+AST group were gavaged with Haematococcus pluvialis (dose of 25m / kg) and astaxanthin (dose of 25m / kg), respectively. The Control group, the 5-FU group, and the 5-FU+TA group were gavaged with distilled water once a day, and fasted for 24h after the last gavage. After fasting, the 5-FU group, the 5-FU+HP group, the 5-FU+AST group, and the 5-FU+TA group were intraperitoneally injected with 5-fluorouracil for modeling at a dose of 150mg / kg. The day of injection of 5-fluorouracil was set as the first day. After modeling, each group was fed in the following manner:

[0044] Control group (normal group, or Con group): distilled water was gavaged from day 4 to day 6, and normal water and feed were given every day for feeding;

[0045] 5-FU group (oral ulcer model group): On the second day, the cheek pouch mucosa was scratched superficially with the tip of an 18-gauge needle, and distilled water was gavaged from the 4th to the 6th day. The mice were fed with normal water and feed every day.

[0046] 5-FU+HP group (Haematococcus pluvialis group): On the second day, the cheek pouch mucosa was scratched superficially with the tip of an 18-gauge needle, and the mice were gavaged with 25 mg / kg of Haematococcus pluvialis from the fourth to sixth days. The mice were also fed with normal water and feed every day.

[0047] 5-FU+AST group (astaxanthin group): On the second day, the cheek pouch mucosa was scratched superficially with the tip of an 18-gauge needle. From the fourth to sixth day, the mice were gavaged with 25 mg / kg astaxanthin. At the same time, they were given normal water and feed every day.

[0048] 5-FU+TA group (triamcinolone acetonide group): On the second day, the cheek pouch mucosa was scratched superficially with the tip of an 18-gauge needle. From the fourth to the sixth day, triamcinolone acetonide was gavaged at a dose of 1 mg / kg. The mice were fed with normal water and feed every day.

[0049] During the modeling and the above treatment process, the mice were weighed. On the 10th day of the above treatment, all rats were anesthetized and killed, and oral mucosal tissue and rat blood were collected. The collected oral mucosa was fixed in 4% paraformaldehyde for dehydration, embedding and slicing to obtain paraffin sections. The sections were stained with hematoxylin-eosin (HE), Masson (Masson) and Sirius Red (SR), respectively. The blue color in the Masson-stained sections represents collagen fibers, and the deposition of collagen fibers in the submucosal matrix was quantitatively analyzed using ImageJ software. Fibrosis (collagen fiber) percentage = collagen fiber area of ​​Masson-stained sections / total area of ​​mucosal tissue × 100%.

[0050] On the last day of the experiment, the oral mucosa of the rats was photographed and observed. The experimental results are shown in Figure 1 (A) in the figure. As can be seen from the figure, the rats in the control group (normal group) did not have ulcers in the oral mucosa, but after induction with the chemotherapy drug 5-FU, a large number of ulcers appeared in the oral cavity of the 5-FU group (oral ulcer model group); the ulcer points in the oral cavity of the Haematococcus pluvialis group were significantly reduced after treatment with Haematococcus pluvialis. The oral ulcers in the astaxanthin group were alleviated after treatment with astaxanthin, but the effect was not as obvious as that in the Haematococcus pluvialis group. The ulcer symptoms in the triamcinolone acetonide group were milder than those in the model group.

[0051] The experimental results of oral mucosa staining sections are as follows Figure 1 As shown in (B), HE results showed that obvious epithelial spikes were visible in the oral mucosa of rats in the Control group, while the spikes in the oral mucosa tissue of rats in the 5-FU group gradually flattened or even disappeared, the epithelium atrophied, and the lamina propria thickened. After treatment with Haematococcus pluvialis (HP), the spikes were significantly restored. SR and Masson staining results showed that the collagen deposition in the buccal mucosa of rats in the 5-FU group was more than that in the Control group, and the collagen deposition was reduced after treatment with Haematococcus pluvialis. This suggests that Haematococcus pluvialis has a protective effect on 5-FU-induced damage to the oral mucosal epithelium and submucosal layer of rats. The HE, SR and Masson staining results of the oral mucosa of rats given astaxanthin (AST) by gavage (5-FU+AST group) were significantly improved compared with the oral ulcer model, but the improvement effect was not as obvious as that of the Haematococcus pluvialis group (5-FU+HP group). Figure 1The right side of (B) shows the collagen fiber content in the mucosal tissue calculated based on Masson staining. It can be seen from the figure that the collagen fiber content in the 5-FU group was significantly increased compared with the Control, while oral administration of Haematococcus pluvialis, astaxanthin and triamcinolone acetonide could effectively reduce the collagen fiber content, among which Haematococcus pluvialis had the best effect.

[0052] Example 3 Haematococcus pluvialis increases the levels of barrier proteins Occludin and ZO-1 in oral mucosal tissues of rats with oral ulcers and human normal oral epithelial keratinocytes

[0053] Experimental materials: oral mucosal tissues of rats from each group collected in Example 2, human normal oral epithelial keratinocytes HOKs (Shanghai Meiwan Biotechnology Co., Ltd.); oral keratinocyte culture medium (Shanghai Meiwan Biotechnology Co., Ltd.).

[0054] Experimental methods:

[0055] Western Blot (WB) was used to detect the expression of Occludin and ZO-1 proteins in the oral mucosal tissues of rats in each group collected after the experiment in Example 2. The Western Blot method described in the present invention is a routine operation in the art and will not be described in detail here.

[0056] LPS-induced HOKs cells (normal human oral epithelial keratinocytes): HOKs cells were seeded in a six-well plate at a density of approximately 2×10 per well. 5 The cells were placed in a cell culture incubator (37°C with 5% carbon dioxide) for 24 hours and then divided into 6 groups:

[0057] Normal group (Control): Remove the old culture medium, add 2 mL of oral keratinocyte culture medium, and culture in a 37°C incubator with 5% carbon dioxide for 24 h;

[0058] Model group (LPS): Remove the old culture medium, add 2 mL of oral keratinocyte culture medium containing 5 μg / mL LPS, and culture in a 37°C incubator with 5% carbon dioxide for 24 h;

[0059] Low-dose group of Haematococcus pluvialis (LPS + 6 μg / mL HP): remove the old culture medium, add 2 mL of oral keratinocyte culture medium containing 5 μg / mL LPS and 6 μg / mL HP, and culture in a 37°C incubator containing 5% carbon dioxide for 24 h;

[0060] Medium-dose group of Haematococcus pluvialis (LPS + 12 μg / mL HP): remove the old culture medium, add 2 mL of oral keratinocyte culture medium containing 5 μg / mL LPS and 12 μg / mL HP, and culture in a 37°C incubator containing 5% carbon dioxide for 24 h;

[0061] High-dose group of Haematococcus pluvialis (LPS+24μg / mL HP): remove the old culture medium, add 2mL of oral keratinocyte culture medium containing 5μg / mL LPS and 24μg / mL HP, and culture in a 37℃ incubator containing 5% carbon dioxide for 24h;

[0062] Astaxanthin (LPS + 12 μg / mL AST): Remove the old culture medium, add 2 mL of oral keratinocyte culture medium containing 5 μg / mL LPS and 12 μg / mL AST, and culture in a 37°C incubator containing 5% carbon dioxide for 24 h;

[0063] After the above treatments were completed, the cell culture supernatant and cells were collected for further experiments.

[0064] Cell immunofluorescence detection: The collected cells were washed twice with PBS, fixed with 4% paraformaldehyde for 15 minutes at room temperature, and permeabilized with 0.5% Triton X-100 in PBS for 15 minutes; then the cells were blocked with 10% goat serum for 30 minutes and incubated with primary antibodies in 10% goat serum at 4°C overnight; then, washed three times with PBS, and incubated with DyLight 488-conjugated AffiniPure goat anti-mouse IgG (H+L) or CY3-conjugated AffiniPure goat anti-rabbit IgG (H+L) in a dark box for 1.5 hours. The cell nuclei were stained with DAPI staining reagent for 15 minutes. Finally, the coverslips with cells were mounted on slides with anti-fading mounting medium. Images were taken by fluorescence microscopy.

[0065] Experimental results:

[0066] The results are as follows Figure 2 As shown, the results of western blotting were consistent with those of oral mucosa pathological section staining. Figure 2The results in (A) and (B) show that compared with the normal group (expressed as Control group or Con group), the expression of epithelial barrier proteins ZO-1 and Occludin in the oral mucosal tissue of rats in the 5-fluorouracil-induced oral ulcer model group (5-FU group) was significantly downregulated; after administration of Haematococcus pluvialis (HP) and astaxanthin (AST), compared with the 5-FU group, the Haematococcus pluvialis group (5-FU+HP group) could significantly promote the production of ZO-1 and Occludin proteins in the oral mucosal tissue of rats with oral ulcers. Compared with the astaxanthin group (5-FU+AST group), the production levels of ZO-1 and Occludin proteins in the Haematococcus pluvialis group were higher. These results show that Haematococcus pluvialis can promote the expression level of barrier-related proteins in the oral mucosa of rats with 5-FU-induced oral ulcers, and its promotion ability is better than astaxanthin at the same dose.

[0067] Immunofluorescence (IF) results Figure 2 (C) shows that the Occludin protein in the Control group is located on the cell membrane, but after LPS treatment, it does not aggregate normally on the cell membrane, and the expression of Occludin protein drops sharply; after treatment with Haematococcus pluvialis, the barrier protein recovers its tight connection and forms a barrier. From the statistical results, the effect of Haematococcus pluvialis treatment is significantly better than that of astaxanthin treatment at the same dose. Figure 2 As can be seen in (D), the peripheral membrane protein ZO-1 of the cells in the Control group is distributed in the cell membrane, forming a tight honeycomb structure with neighboring cells. After LPS treatment, the ZO-1 protein in the LPS group showed abnormal distribution, and the honeycomb structure was destroyed and gradually disappeared, indicating that its tight junction barrier was destroyed and ZO-1 expression was significantly reduced; after treatment with Haematococcus pluvialis, the barrier protein restored the honeycomb structure, and the effect of Haematococcus pluvialis treatment at the same dose was significantly better than that of astaxanthin treatment.

[0068] Example 4 Haematococcus pluvialis reduces the levels of inflammatory factors TNF- and IL-6 in rat mucosal tissue induced by 5-fluorouracil and in human normal oral epithelial keratinocytes induced by lipopolysaccharide

[0069] Experimental materials: oral mucosal tissues of rats from each group collected in Example 2, and culture supernatant of normal human oral epithelial keratinocytes collected in Example 3.

[0070] Experimental method: Rat interleukin 6 (IL-6) ELISA Kit, human tumor necrosis factor α (TNF-α) ELISA Kit, and human interleukin 6 (IL-6) ELISA Kit were used to detect the IL-6 and TNF-α levels in normal human oral epithelial keratinocytes.

[0071] Experimental results:

[0072] Figure 3 (A) and (B) in the figure are the levels of IL-6 and TNF-α in the culture supernatant of normal human oral epithelial keratinocytes. It can be seen from the figure that the levels of IL-6 and TNF-α in the supernatant of cells in the LPS group increased significantly (p<0.001), indicating that the cells showed inflammatory response after LPS induction; and after intervention with Haematococcus pluvialis (HP) or astaxanthin (AST), the levels of IL-6 and TNF-α could be significantly reduced (p<0.001), among which, at the same dose, the reduction effect of Haematococcus pluvialis was better than that of astaxanthin.

[0073] Figure 3 As can be seen from (C), after induction by 5-fluorouracil (5-FU), the inflammatory factor IL-6 in the oral mucosa of rats was significantly increased (p<0.001), while intervention with Haematococcus pluvialis (HP), astaxanthin (AST) and the positive drug triamcinolone acetonide (TA) could significantly reduce the IL-6 content (p<0.001), among which intervention with Haematococcus pluvialis (HP) had the best effect on reducing the IL-6 content, which was significantly better than astaxanthin and triamcinolone acetonide.

[0074] The above experimental results show that Haematococcus pluvialis has a good therapeutic effect on 5-fluorouracil-induced oral ulcers and LPS-induced oral inflammation, which is specifically manifested in that it can significantly reduce the content of inflammatory factors. Moreover, at the same dose, the therapeutic effect of Haematococcus pluvialis intervention is better than astaxanthin.

[0075] Example 5 Haematococcus pluvialis regulates the mitochondrial inflammatory pathway cGAS-STING

[0076] Experimental materials: cells collected in Example 3.

[0077] Experimental method: The proteins in the cells collected in Example 3 were extracted, and the protein expression levels of cGAS, STING and TBK1 in normal human oral epithelial keratinocytes were detected by western blotting (WB).

[0078] Experimental results:

[0079] When the amount of DNA in the cytoplasm increases abnormally, cGAS will recognize it and undergo conformational changes. It will then use ATP and GTP as reaction substrates to catalyze the production of the second messenger cGAMP in the cytoplasm. Next, cGAMP binds to STING (interferon gene stimulating protein) on the endoplasmic reticulum and changes its conformation. It then translocates to the Golgi apparatus to activate TANK binding kinase 1 (TBK1). TBK1 phosphorylates itself and in turn activates the STING protein, causing it to also be phosphorylated, thereby interfering with the expression of some related genes in the cGAS-STING signaling pathway, activating the inflammatory pathway cGAS-STING, and causing the body to produce an inflammatory response. Figure 4 As can be seen from (A), (B), and (C), after LPS induction, the STING protein, cGAS protein, and P-TBK1 protein in the cells increased sharply, while after intervention with Haematococcus pluvialis (HP) or astaxanthin (AST), the expression of STING protein, cGAS protein, and P-TBK1 protein decreased significantly compared with the LPS group, indicating that Haematococcus pluvialis (HP) and astaxanthin (AST) can inhibit the activation of the mitochondrial inflammatory pathway cGAS-STING, thereby reducing the level of oral inflammatory factors and improving the oral mucosal barrier function.

[0080] The above embodiments are preferred implementation modes of the present invention, but the implementation modes of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principles of the present invention should be equivalent replacement methods and are included in the protection scope of the present invention.

Claims

1. Application of Haematococcus pluvialis in the preparation of drugs for the prevention and treatment of oral ulcers.

2. The application according to claim 1, characterized in that: The oral ulcer is a chemotherapy-induced oral ulcer or a lipopolysaccharide LPS-induced oral ulcer.

3. The application according to claim 1, characterized in that: The chemotherapy-induced oral ulcer is induced by chemotherapy drugs.

4. The use according to claim 3, characterized in that: The chemotherapy drug is one or more of 5-fluorouracil, methotrexate, cyclophosphamide and irinotecan.

5. The use according to claim 1, characterized in that: The method for preventing and treating oral ulcers is to increase the expression levels of Occludin and ZO-1 proteins.

6. The use according to claim 1, characterized in that: The method for preventing and treating oral ulcers is to reduce the content of inflammatory factors IL-6 and TNF-α.

7. The use according to any one of claims 1 to 6, characterized in that: The drug also includes pharmaceutically acceptable excipients.

8. The use according to any one of claims 1 to 6, characterized in that: The dosage form of the drug is oral patch, oral lozenge, mouthwash, spray, ointment, oral preparation or injection.

9. Use of a pharmaceutical composition in the preparation of a drug for preventing and treating oral ulcers, characterized in that: The pharmaceutical composition comprises Haematococcus pluvialis.

10. The use according to claim 9, characterized in that: The pharmaceutical composition also includes pharmaceutically acceptable excipients.

Citation Information

Patent Citations

  • Natural haematococcus pluvialis astaxanthin soft capsule

    CN107157969A

  • Application of astaxanthin in preparation of preparation for protecting oral mucosal barrier

    CN115887432A

  • Anti-inflammatory agent containing astaxanthin

    KR1020120133661A

  • Compositions and methods comprising stable reduced glutathione

    US20230165928A1